الشركات المدرجة في الأسفل تجري أختبارات على أدوية متنوعة، و من الممكن أن تنجح أو تفشل: ViroPharma (NASDAQ: VPHM): The Common Cold. ViroPharma is developing Picovir, purported to be the magic cure for the common cold. The company specializes in novel therapeutics for the treatment of diseases caused by RNA viruses. Such viruses are responsible for a host of common disorders, including certain types of meningitis, hepatitis, and the common cold. Many analysts feel an approval could be coming late this year for Picovir. Maxim Pharmaceuticals (NASDAQ: MAXM): Cancer Therapy. The Company's lead drug candidate, Ceplene™, is currently being tested in Phase 3 cancer clinical trials in 12 countries for malignant melanoma and acute myelogenous leukemia, and in Phase 2 trials for the treatment of hepatitis C and renal cell carcinoma. Medarex (NASDAQ: MEDX): Arthritis. Phase III trials were recently started on MDX-CD4, a treatment for rheumatoid arthritis. MDX-010 is currently undergoing several multi center Phase Phase I/II trials in prostate cancer, melanoma and other malignancies. Axcan Pharma (NASDAQ: AXCA): Ulcers and Other Stomach Problems. Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and Europe. This company posted fiscal year revenues of $104.5 million dollars and earnings of $11.5 million. Helicide, Axcan's patented, oral, single capsule, triple therapy treatment for H. Pylori infection (the leading cause of peptic ulcers and a potential cause of gastric cancer) should be FDA approved later this year. DUSA Pharmaceuticals (NASDAQ: DUSA): Cancer Detection. The company's main product Levulan® PDT/PD is a platform used for the detection and treatment of a variety of superficial conditions, such as early cancers, pre cancers and skin conditions. Levulan apparently has wider applications and may add to the bottom line in the not too distant future. DUSA initiated three Phase I/II Levulan PDT clinical trials.